Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early alirocumab in acute atherosclerotic ischemic stroke
KCT0009238Phase 4Terminated
- Sponsor
- Asan Medical Center
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of alirocumab in ischemic stroke, brain infarction, atherosclerosis, sponsored by Asan Medical Center. Started Oct 2024; status: terminated.
02
Drugs
alirocumab
03
Conditions
ischemic strokebrain infarctionatherosclerosis
Beyond the preview
Go deeper on KCT0009238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0009238.